NASDAQ
2.96USD
-0.07 (-2.31%)
We have scored 5 news catalysts on Entera Bio Ltd. (ENTX) over the past 12 months. The biggest single-day move next to one of them came Jul 27, 2026, when ENTX closed +91.2%: “Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June”. Coverage across the window leans positive (average ticker sentiment +0.84). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
145.9M
P/E
—
EPS
—
Beta
1.39
52W range
0.91-4.2
Day range
2.88–3.14
Open
3.07
Prev close
3.03
Volume
289K
Avg volume
2.6M
Dividend
0.00
IPO
2018-06-28
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Entera Bio Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ENTX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
